Physician profile
Robert C Mcgarvey
NPI 1568618171
$4,685.92
in general payments reported to CMS, 2019-2025
21 companies · $803 in 2025
The $803 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $325 · 2021: $655 · 2022: $749 · 2023: $767 · 2024: $655 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,579.66 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Coopervision INC. | $658.36 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $440.49 | 2022-2025 | Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $341.52 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $268.70 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $240.74 | 2019-2023 | |
| Abb Con-Cise Optical Group LLC | $233.98 | 2019-2025 | Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $206.46 | 2019-2021 | |
| Abbvie INC. | $127.63 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $105.79 | 2023-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $84.70 | 2019-2021 | |
| Biotissue Holdings INC. | $82.13 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $63.63 | 2021-2025 | |
| Carl Zeiss Meditec USA, INC. | $59.97 | 2024 | Cirrus Hd-Oct |
| Allergan, INC. | $58.66 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $42.17 | 2022-2023 | Tepezza |
| Maculogix, INC. | $25.14 | 2019 | |
| Dompe US, INC. | $17.34 | 2024 | Oxervate |
| Lkc Technologies, INC. | $16.43 | 2025 | |
| Alcon Research LLC | $16.43 | 2019 | |
| Sight Sciences, INC. | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcgarvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.